DERADEX
DEAD

Serial Number

87827723

Owner

EXCIVA UG (haftungsbeschränkt)

Attorney

SREENIVASARAO VEPACHEDU

First Use Date

Jul 2, 2018

Filing Date

Mar 9, 2018

Add to watchlist:

No watchlists yet
View on USPTO

DERADEX Trademark

Serial Number: 87827723 • Registration: 5735100

DERADEX is a trademark filed by EXCIVA UG (haftungsbeschränkt) on March 9, 2018. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

EXCIVA UG (haftungsbeschränkt) (6 trademarks)

1230 GEORGETOWN WAY
VERNON HILLS, IL 60061

Entity Type: 16

EXCIVA GMBH (5 trademarks)

1230 GEORGETOWN WAY
VERNON HILLS 69118 , DE

Entity Type: 27

Trademark Details

Filing Date

March 9, 2018

Registration Date

April 23, 2019

First Use Anywhere

July 2, 2018

First Use in Commerce

July 2, 2018

Published for Opposition

July 24, 2018

Cancellation Date

November 7, 2025

Goods & Services

Allergy medications; Amino acid preparations for medical purposes; Antiallergic medicines; Cardiovascular agents for medical purposes; Cardiovascular pharmaceuticals; Cardiovascular treatment preparations; Dietary and nutritional supplements; Medical diagnostic reagents; Medical diagnostic reagents and assays for testing of body fluids; Medical diagnostic reagents for the analysis of body fluids; Nutraceuticals for use as a dietary supplement; Nutritional supplements; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents for epidermis; Pharmaceutical agents for treating physically caused lesions; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical antitussive-cold preparations; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for skin care; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for ocular or intraocular surgery; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for reducing sexual activity; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of hypercholesteremia; Pharmaceutical preparations for the treatment of hyperlipidemia; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for the treatment of musculo-skeletal disorders; Pharmaceutical preparations for the treatment of worms in pets; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for knee cartilage regeneration; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for treating dandruff; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical preparations for wounds; Pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, a topical preparation for the treatment of ocular disorders prescribed by ophthalmologists, eye surgeons, and optometrists; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Pharmaceutical preparations, namely, anticoagulants; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical preparations, namely, antivirals; Pharmaceutical preparations, namely, appetite suppressants; Pharmaceutical preparations, namely, dantrolene sodium for injection; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical products and preparations against dry skin caused by pregnancy; Pharmaceutical products and preparations for chloasma; Pharmaceutical products and preparations for hydrating the skin during pregnancy; Pharmaceutical products and preparations for pregnancy blemishes; Pharmaceutical products and preparations for preventing skin blemishes during pregnancy; Pharmaceutical products and preparations to prevent stretch marks; Pharmaceutical products and preparations to prevent swelling in the legs; Pharmaceutical products for ophthalmological use; Pharmaceutical products for skin care for animals; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for treating respiratory diseases; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical skin lotions; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals, namely, antihelmintics; Pharmaceuticals, namely, inducers of erections; Pharmaceuticals, namely, lipid lowering agents; Pharmaceuticals, namely, psychotropics; Preparations for the suppression of hormones; Preparations for the treatment of asthma; Preparations for the treatment of burns; Preparations for treating colds; Preparations to prevent nail-biting and thumb-sucking; Prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of cardiovascular disorders

Filing History

CANCELLED SEC. 8 (6-YR)
Nov 7, 2025 C8..
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Apr 23, 2024 REM1
REVIEW OF CORRESPONDENCE COMPLETE - INFORMATION MADE OF RECORD
Jun 11, 2020 CORV
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
May 13, 2020 APRE
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Mar 8, 2020 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 8, 2020 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Mar 8, 2020 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 8, 2020 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 8, 2020 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Mar 8, 2020 COAR
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Aug 7, 2019 ASGN
REGISTERED-PRINCIPAL REGISTER
Apr 23, 2019 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Mar 20, 2019 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Mar 19, 2019 CNPR
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 15, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 15, 2019 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Mar 5, 2019 ERFR
NOTIFICATION FOR REQ FOR RECON DENIED NO APPEAL FILED
Mar 5, 2019 RDX3
ACTION FOR REQ FOR RECON DENIED NO APPEAL FILED E-MAILED
Mar 5, 2019 RDX1
ACTION REQ FOR RECON DENIED NO APPEAL FILED COUNTED NOT MAILED
Mar 5, 2019 RRDX
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 5, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 5, 2019 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Mar 1, 2019 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Feb 25, 2019 GNFN
FINAL REFUSAL E-MAILED
Feb 25, 2019 GNFR
SU - FINAL REFUSAL - WRITTEN
Feb 25, 2019 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 25, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 25, 2019 CRFA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Feb 25, 2019 CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Feb 25, 2019 CHAN
ASSIGNED TO LIE
Feb 22, 2019 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 18, 2019 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 5, 2018 GNRN
NON-FINAL ACTION E-MAILED
Dec 5, 2018 GNRT
SU - NON-FINAL ACTION - WRITTEN
Dec 5, 2018 CNRT
STATEMENT OF USE PROCESSING COMPLETE
Dec 1, 2018 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Dec 1, 2018 AITU
USE AMENDMENT FILED
Nov 14, 2018 IUAF
TEAS STATEMENT OF USE RECEIVED
Nov 14, 2018 EISU
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Sep 18, 2018 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 24, 2018 NPUB
PUBLISHED FOR OPPOSITION
Jul 24, 2018 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 4, 2018 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 21, 2018 CNSA
ASSIGNED TO EXAMINER
Jun 21, 2018 DOCK
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Apr 3, 2018 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Apr 3, 2018 REAP
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 15, 2018 TCCA
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 15, 2018 NWOS
NEW APPLICATION ENTERED
Mar 13, 2018 NWAP